Clinical trials: Borderline Resectable Pancreatic Carcinoma
Locally Advanced Malignant Neoplasm
Chemoimmunotherapy and Radiation in Pancreatic Cancer
The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.
- Trial name
- CRIT (NCT01903083)
- Testing
- Tadalafil, Gemcitabine, Radiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Providence Health & Services
Pancreatic Cancer
GTX-RT in Borderline Resectable Pancreatic Cancer
The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at participant's tumor followed by more…
- Trial name
- NCT01754623
- Testing
- Capecitabine, Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Borderline Resectable Pancreatic Cancer
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer
This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU/LV in perioperative treatment of borderline resectable pancreatic cancer in…
- Trial name
- undetermined (NCT06387810)
- Testing
- irinotecan liposome II combined with 5-FU/LV and oxaliplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer, Adult
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. Led by The First Affiliated Hospital with Nanjing Medical University and Peking University Cancer Hospital \& Institute (as leading centers)…
- Trial name
- NOTABLE-309 (NCT07277452)
- Testing
- Nimotuzumab, AG regimen
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
- Trial name
- NCT02843945
- Testing
- Directional Brachytherapy Source Implant
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- CivaTech Oncology
Pancreatic Cancer
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Multicenter Prospective Phase II Study for Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer RATIONALE: Borderline resectable pancreatic cancer is frequently related to a positive surgical…
- Trial name
- NCT02459652
- Testing
- S-1, Radiation Therapy
- Where
- 22 sites in Japan
- Volunteers
- 57 people
- Sponsor
- Japan Adjuvant Study Group of Pancreatic Cancer
Borderline Resectable Pancreatic Cancer
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and…
- Trial name
- NCT02241551
- Testing
- gemcitabine/nab-paclitaxel, mFOLFIRINOX
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nathan Bahary, MD
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline
EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer
This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
- Conditions
- Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline, Pancreatic Cancer Resectable
- Trial name
- NCT07698613
- Testing
- ASP-1929 photoimmunotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brown University
Pancreatic Cancer
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer.
- Trial name
- NCT00761241
- Testing
- Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Pancreatic Cancer, Adult
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer
- Trial name
- NCT07436741
- Testing
- surufatinib + gemcitabine + nab-paclitaxel, gemcitabine + nab-paclitaxel
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgical removal) or borderline…
- Trial name
- UVA-PC-PD101 (NCT02305186)
- Testing
- Pembrolizumab, Neoadjuvant Chemoradiation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Craig L Slingluff, Jr
Borderline Resectable Pancreatic Cancer
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
This study was a single-arm multicenter prospective phase II clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03850769
- Testing
- nab-paclitaxel and S-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a…
- Trial name
- NCT07671339
- Testing
- ELI-002 7P, Tislelizumab, mFOLFIRINOX
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced …
- Trial name
- ARTIA-Pancreas (NCT05764720)
- Testing
- Daily Adaptive External Beam Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 134 people
- Sponsor
- Varian, a Siemens Healthineers Company
Pancreatic Carcinoma
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
This is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies.
- Trial name
- NCT02676349
- Testing
- mFolfirinox, Chemoradiotherapy, surgery
- Where
- 26 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut de Cancérologie de Lorraine
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT04484909
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
<Research Hypothesis> The dynamics of immune cells by CCRT/Durvalumab will be uncovered. The combination of Durvalumab with concurrent chemoradiotherapy (CCRT/gemcitabine)) as neoaduvant treatment in resectable or borderline…
- Trial name
- NCT03572400
- Testing
- Gemcitabine, Durvalumab
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Do-Youn Oh
Pancreas Cancer, Adenocarcinoma
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
Despite important therapeutic advances, pancreatic adenocarcinoma remains one of the cancers with a high mortality rate (4th leading cause of cancer death in the US in 2021), poor prognosis (5-year overall survival rate of 10%)…
- Trial name
- ReMeTTI (NCT05511116)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
This pilot clinical trial studies stereotactic radiosurgery and metformin hydrochloride in treating patients with pancreatic cancer that may be removed (borderline-resectable) or not removed by surgery.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I-III Pancreatic Cancer
- Trial name
- NCT02153450
- Testing
- metformin hydrochloride, stereotactic radiosurgery
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Adenocarcinoma
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil (5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure of the cancer to a broader array of potentially…
- Trial name
- NCT03703063
- Testing
- Gemcitabine, nab paclitaxel, Onivyde
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benaroya Research Institute